Celltech - Pharma

• Codeprex filing 2001 - FDA decision expected H2-2002

Cough/Cold £74 million +27%

• Metadate® CD - over 9% share once-daily MPH market (equivalent to some $25 million sales annualised)

• Comparative study with Concerta® mid-2002

• Sprinkle formulation approved

ADHD £29.0 million +10%

Previous slide

Next slide

Back to first slide

View graphic version